



Therakine, Ltd. Files Additional Patents

September 4, 2013

Therakine, Ltd., a privately held drug delivery company founded in June, 2006, has developed novel drug delivery technology for biologics and small molecules that address drug delivery challenges in multiple therapeutic areas. The Company has multiple patents approved and pending, and today announced the filing of additional patents for sustained release formulations as a toolkit.


TheraKine has developed sustained release delivery technology platforms for the local delivery of biologic agents and small molecules. Linear release of drug products with durations from weeks to months is now possible using TheraKine's tunable, sustained-release technologies.

TheraKine's platform: (i) achieves greater stability through the exploitation of the biophysical properties of the underlying molecules; (ii) enables sustained linear release for weeks to months as needed for best therapeutic outcomes; (iii) has been able to achieve higher drug concentrations than earlier approaches which translates to smaller overall parcels for the site-specific delivery; and (iv) uses only existing approved GRAS excipients to reduce regulatory burdens.

- TheraKine's hydrophilic matrix system is designed for short and medium term release applications while
- TheraKine's hydrophobic matrix system covers medium and long-term release applications.
- TheraKine's tunable sustained release technology now enables linear release for controlled and predictable pharmacokinetics, of drug products with durations from weeks to many months.

We are able to "tune" the release kinetics and achieve linear, burst or combined profiles to satisfy most therapeutic requirements for local drug delivery. All formulations use existing approved ingredients that are generally regarded as safe (GRAS). This will minimize regulatory overheads, safety concerns, and costs of development and trials.

No chemistry is involved. The formulation exploits the properties of the active ingredient to achieve long release without any changes to the active ingredient.





Stan Yakatan, CEO of Therakine stated, “We think this action shall allow all of the Therakine entities to more fully pursue its patent prosecution and its intellectual property estate. “

Over the past six months, the Therakine team has accelerated its licensing negotiations, achieved several clinical milestones, and has worked to improve its balance sheet; all of which have been fundamental advancements of the Company’s business. However, we remain focused on the goal of unlocking significant stockholder value.”